Immune Checkpoint Inhibitor–Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study

Introduction: Immune checkpoint inhibitors (ICIs) have substantially improved the clinical outcomes of various malignancies. However, the adverse event of tumor lysis syndrome (TLS) has not been included in the National Comprehensive Cancer Network guidelines or drug inserts. In this study, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li, Li, Xiaolin, Zhao, Bin, Mei, Dan, Jiang, Jiandong, Duan, Jingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495237/
https://www.ncbi.nlm.nih.gov/pubmed/34630077
http://dx.doi.org/10.3389/fphar.2021.679207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495237/
https://www.ncbi.nlm.nih.gov/pubmed/34630077
http://dx.doi.org/10.3389/fphar.2021.679207

Ejemplares similares